ArticleChinese medical journal2026

Efficacy and safety of secukinumab in patients with active psoriatic arthritis at Week 16 and up to 52 weeks: Results from a Phase III, randomized, double-blind, placebo-controlled bridging study in China.

Xiaomei Leng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.